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Abstract Rapid diagnosis ofMycobacterium tuberculosisremains an obstacle for therapyof tuberculosis (TB). Adeno-
sine deaminase isoform 2 (ADA2) is produced by activated macrophages and has been used for diagnosis of TB from
extra-pulmonary sites.However, few studies adequately addresswhether serum ADA2 activity is useful fordiagnosis of
active pulmonary tuberculosis (PTB).We prospectivelymeasured serum ADA2 activity in110 patients with pulmonary
disease (65 cases with active PTB and 45 cases with other respiratory diseases) and 78 healthy volunteers (eight with
tuberculin skin test positive). The serum ADA2 for the diagnosis of PTB had the sensitivity of 36?9%, the specificity
of 84?5%, the positive predictive value of 10?9% and the negative predictive value of 96?2%.We concluded that
serum ADA2 activity is neither useful to diagnosis of active PTB nor to differentiate from other respiratory diseases.
r 2002 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2001.1273, available online at http://www.idealibrary.comon
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Pulmonary tuberculosis (PTB) remains one of the leading
causes ofmorbidity andmortality worldwide accounting
for approximately 8 million new cases and 2 million
deaths each year (1). Although mycobacterial culture is
sensitive and the standard for diagnosing tuberculosis
(TB), the time to diagnosis requires a minimum of 2^3
weeks, and the acid-fast bacilli (AFB) smear, the rapid
screening method for the diagnosis of PTB, is insensitiv-
ity for detecting mycobacteria amongTB patients with
non-cavitary disease (2). Compounding the need for
better laboratory diagnosis of PTB is the di⁄culty to
clinically discriminateTB from non-TB infectious respira-
tory diseases or lung cancer.
Adenosine deaminase (ADA, adenosine aminohydro-
lase, EC 3?5?4?4) is an enzyme released by monocyte/
macrophages that transforms, respectively, adenosineCorrespondence should be addressed to:Dr Marcus B.Conde. Av.
BrigadeiroTrompowsky, s/n1, 31 andar, SME da Pneumologia, Ilha do
Funda4 o, Rio de Janeiro, RJ, Brazil,CEP 21941-590.Fax: (55 21) 22702193;
E-mail: marcusconde@huc¡.ufrj.brand deoxyadenosine to inosine and deoxyinosine (3).
The increased serum level of ADA has been reported
for viral and bacterial pneumonia, for HIV-infection and
for extra-pulmonaryTB (3,4). In fact, diseases caused by
intracellular micro-organisms are characterized by an
elevated level of ADA in serum (3). SinceMycobacterium
tuberculosis (Mtb) infects lungmacrophages, ADAmaybe
released andbe detectedin serumofpatientswith active
PTB. There is limited data on the use of serum ADA
levels to diagnose active PTB in adults (5).Two studies in
children reported that serum ADA levels in PTB but
they lackedappropriate comparison to other respiratory
diseases (6,7).The purpose of this study was to evaluate
whether total serum level of ADA or ADA2 activity can
discriminate active PTB from other lung diseases and
from healthy volunteers.
METHODS
Prospectively, 135 subjects (age 18yrs and older) who
presented for evaluation of pulmonary disease at the
Pulmonary Diseases Unit, Hospital Universitario
608 RESPIRATORYMEDICINEClementino Fraga Filho (HUCFF) ofUniversidade Feder-
al do Rio de Janeiro (UFRJ), Brazil, and had respiratory
symptoms and radiographic ¢ndings suggestive of PTB
were enrolled after informed consent andbloodwas ob-
tained. In addition, blood samples of 78 symptom-free
healthy subjects without history of active PTBwere also
included as controls. The study was approved by the
Ethics Committee of HUCFF/UFRJ. Serum separated
from blood from each subject was stored at 201C and
thaw once for the ADA assay.
On study enrollment, the135 patients with symptoms
and signs of respiratory disease were administered a
questionnaire, received a physical examination, chest
radiograph, and HIV test (withWestern Blot con¢rma-
tion) and a sputum was collected for routine bacterial
culture, mycobacterial culture and AFB smear. Patients
unable to expectorate spontaneously underwent
sputum induction (SI) or ¢bre optic bronchoscopy with
bronchoalveolar lavage (BAL) performed by clinicians
not involved with the research. All healthy controls
received a tuberculin skin test (TST) using 2TU of Puri-
¢ed Protein Derivative (PPD Rt-23, 2 TU, Serum Insti-
tute, Denmark) and induration equal to or greater than
10mmwas considered positive.
All respiratory specimens were stained with haema-
toxylin and eosin, Papanicolaou, Ziehl-Neelsen stain,
Grocot’s methenamine silver stain, and were cultured in
L˛wenstein Jensen, Sabouraudmedium, and routine bac-
terial culture following standardprotocol.The specimens
cultured positive for mycobacteria were speciated by
standard biochemical methods. Active PTB was de¢ned
as a positive culture for Mtb in one or more pulmonary
specimen and resolution of clinical and/or radiographic
abnormalities after 3months of standard anti-tuberculo-
sis treatment. Inactive (pulmonary scarring) PTB was
de¢ned as negative mycobacterial culture with un-
changed chest radiographic ¢ndings consistent with
healed tuberculosis. A diagnosis of bacterial, fungal or
viral infections was made on the basis of clinical, radio-
graphic, and laboratory ¢ndings associated with clinical
and/or radiographic resolution of abnormalities afterTABLE 1. Gender, age, total ADAvalue andnumberof cases of A
Groups (n) Gender Age
male mean7
(yrs)
Active PTB (65) 23 38?471
Other respiratorydiseases (45) 19 44?571
Healthy volunteers (78) 39 23?977
PTB=pulmonary tuberculosis; SD=standarddeviation;ADA=a
n=numberof cases; a vs. c (P=0?001); a vs. b (P=1?0); b vs. c (P=0treatment with antimicrobial therapy other than anti-
TB drugs or only with supportivemeasures.Lung cancer
was diagnosed by histopathology or cytopathology
examination of specimen obtained by bronchoscopy.
Patients were excluded if the HIV test was positive or if
during the 3 months prior to enrollment have received
any antibotic treatment for more than 1 week. All en-
rolled patients were followed for at least 6 months.
ADA activity was determinedaccording to theGiusti’s
method (8). When high ADA activity was detected,
isoenzymes were di¡erentiated according to Gakis’
methodology (3). The mean serum ADA levels for each
group was assessed by one way ANOVA test. The diag-
nostic usefulness of ADAwas assessed in terms of sensi-
tivity and speci¢city. Positive and negative predictive
valueswere calculatedbased on an estimated prevalence
of 5% of active pulmonary TB among patients with re-
spiratory symptoms in Brazil (9).The cuto¡ ADA2 levels
for diagnosis was obtained from the receiver operating
characteristic (ROC) curvemethod.
RESULTS
One hundred and ten patients out of the 135 with pul-
monary symptoms suggestive of PTB were evaluable.
Twenty-¢ve patients were excluded because of incom-
plete follow-up (18 cases), previous anti-TB treatment
(three cases) and lost pulmonary specimens (four cases).
The analysis of ADA levels used the110 available patients.
Sixty-¢ve patients had active PTB and 45 patients were
found to have other respiratory disease: inactiveTB (12),
acute infectious pneumonitis (21), lung cancer (11) and
paracoccidioidomycosis (1). Of the 78 healthy controls,
eight were tuberculin skin test positive. Patients with
other respiratory diseases tended to be older than
eitherTB patients or healthy controls (Table1).
TheADAlevels for eachgroup arepresented asmeans
and as absolute value (Table 1, Fig. 1). The serum ADA
activity cuto¡ value for the diagnosis of PTB established
by the ROCcurvemethod14U/l.Forty ninepercent (32/DA and ADA2 among188 individuals studied
ADA
SD mean7SD ADA414 ADA2414
(U/l) U/l
n
U/l
n
4?9 16?579?9 (a) 32 24
3?5 15?679?1 (b) 20 14
?3 11?476?3 (c) 23 5
denosinedeaminase;ADA2=adenosinedeaminaseisoform 2;
?02)
FIG. 1. ADA total value by group of subjects. HV: healthy
volunteers; ORD: other respiratory diseases; TB: pulmonary
tuberculosis.
SERUMADA2 INPULMONARY TUBERCULOSIS 60965) of patientswith active PTB had serumvalues of ADA
levels above14 U/l. In addition, 44?4% (20/45) of patients
with other respiratory diseases had ADA levels above
the cuto¡ point.Of the healthy controls, 29?5% (23/78)
were above the cuto¡ value. Although ADA levels discri-
minated patients with active PTB from healthy controls,
similar mean ADA levels were found between patients
with active PTB and patients with other respiratory
diseases.We also utilized the cuto¡ pointof14U/l of total
ADA and ADA isoform-2 (ADA2) to evaluate the sensi-
tivity and speci¢city of the assay.The sensitivity of ADA
for diagnosing active PTB is 36?9% [95% con¢dence inter-
val (CI); 33?3%^40?4%] and the speci¢city was 84?5%
[95% CI; 81?8%^87?1%]. If the prevalence of PTB for
patientswith respiratory symptoms is 5%, the calculated
positive predictive value (PPV) is10?9% and the negative
predictive value (NPV) is 96?2%.
DISCUSSION
Monocyte/macrophage activation by intracellular infec-
tion and in£ammatory diseases leads to the release of
ADA and elevated levels in serum. Although the ADA
assay has been reported forTB using pleural, pericardial
and meningeal £uids, few studies with appropriate com-
parison controls have critically evaluated serum ADA
levels as a diagnostic tools for active PTB.Using an ADA
cut-o¡ obtainedby ROCmethod of14 U/l, we found that
49?2% (32/65) patients with active PTB had serum ADA
value signi¢cantly elevated (P=0?001) compared to
healthy controls. Similar ¢ndings were reported by Col-
lazos et al. (5) in which 52% (13/25) patients with activePTB had serum ADA above the upper normal limit.
However, in our study, the mean serum ADA value
among patients with active TB was similar to patients
with other respiratory diseases (P=1?0). This result is in
disagreement with the report by Yasuhara et al. (10) in
which serum ADA activity of children with active PTB
was found to be signi¢cantly greater than those with
bacterial or viral pneumonia. Possible explanations for
the di¡erences found between our study and that of
Yasuhara et al. may include our older sample age, di¡er-
ent ethnicity and the prevalence of di¡erent respiratory
diseases.
Our ¢ndings of low sensitivity (36?9%) andlowpositive
predictive value (10?9%) of serum ADA2 activity for the
diagnosis of active PTB suggest that ADA is not clinically
relevant. Although two other studieshavereported that
serum ADA level in children had a sensitivity level of
100% in diagnosing active PTB, these series have not
included a comparison group with other respiratory
diseases (6,7). The ¢nding of a negative predictive value
of 96% means that most individuals with ADA2 equal or
below 14 U/l did not have active PTB. The negative
predictive value of ADA is likely to be accurate because
a large sample of controls was used in this study. How-
ever, additional studies are needed in order to evaluate
the utility of serum ADA2 as measured to exclude TB.
We concluded that serum ADA2 activity is increased in
about half of all adults with active PTB, but was unable
to di¡erentiate active PTB from other respiratory dis-
eases, and likely not to be clinically useful inTB prevalent
areas.
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